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Clinics and pathology 
Phenotype / cell stem origin 
Alveolar rhabdomyosarcoma (ARMS). 
Epidemiology 
Occurs in ~60% of ARMS cases; patients tend to be 
older children (and young adults) compared to those 
with t(1;13)-positive ARMS tumors. 
Clinics 
Tumors tend to show higher invasiveness compared to 
those with t(1;13)-positive ARMS tumors. In metastatic 
cases. there is a high incidence of bone marrow 
involvement. 
Prognosis 
Outcome is worse than in rhabdomyosarcoma cases 
without a translocation (including embryonal 
rhabdomyosarcoma and translocation-negative ARMS). 
In one study, patients with localized t(2;13) and 
t(1;13)-positive ARMS had comparable outcomes 
whereas a recent study with small numbers suggested 
that localized t(1;13) tumors had a better outcome than 
those with localized t(2;13) tumors. Among patients 
presenting with metastatic disease, those with t(2;13)-
positive tumors had a significantly poorer outcome than 
those with t(1;13)-positive tumors. Note: these studies 









Reciprocal balanced translocations are generally 
present in cases with the associated molecular fusion. 
 
Diagram of t(2;13)(q35;q14) chromosomal translocation. 
Cytogenetics Molecular 
The product of the 2;13 translocation is amplified in 
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Additional anomalies 
Amplification events involving 2p24 and 12q14 (as 
determined by DNA-based array studies). 










Transcription factor - forkhead box (FOX) family. 




A variant PAX3-FOXO4 fusion (also known an PAX3-
AFX1) associated with a t(X;13)(q13:q35) has been 
identified in one ARMS case. 
 
Description 
The 2;13 translocation breaks within intron 7 of the 
PAX3 gene and intron 1 of the FOXO1 gene on 
chromosome 13 to generate PAX3-FOXO1 fusion gene 
as well as a reciprocal FOXO1-PAX3 fusion gene. In 
~10% of PAX3-FOXO1-positive ARMS tumors, the 
FOXO1-PAX3 gene is not detectable. 
Transcript 
The PAX3-FOXO1 fusion transcript consists of the 
first 7 exons of PAX3 fused to FOXO1 exons 2 and 3, 
and the FOXO1-PAX3 fusion transcript consists of the 
first exon of FOXO1 fused to the last two exons of 
PAX3. In ~35% of PAX3-FOXO1-positive ARMS 
tumors (with evidence of PAX3-FOXO1 transcript), 
the FOXO1-PAX3 transcript is not detectable. There is 
evidence that the PAX3-FOXO1 fusion transcript is 
upregulated relative to the wild-type PAX3 transcript 
by a transcriptional mechanism. 
Fusion Protein 
Description 
The PAX3-FOXO1 fusion gene has a 2508 nt open 
reading frame encoding an 836 amino acid fusion 
protein. This fusion protein is a transcription factor 
with a PAX3 DNA binding domain and FOXO1 
transactivation domain. 
Expression / Localisation 
Nuclear. 
 
Generation of chimeric genes by the 2;13 translocation in ARMS. The exons of the wild-type and fusion genes are shown as boxes 
above each map and the translocation breakpoint distributions are shown as line segments below the map of the wild-type genes. 
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Oncogenesis 
Transcription dysregulation. At the cellular level there 
is evidence of alterations in control of growth, survival, 
differentiation, and motility. In conjunction with other 
genetic changes, recipient cells show transformation in 
culture and tumorigenesis in injected mice. A 
conditional knock-in mouse model of the PAX3-FKHR 
fusion has been generated and successfully produces 
ARMS tumors. 
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